1. Cburn JW, Llach F. Renal osteodystrophy and maintenance dialysis in replacement of renal function by dialy¬sis Drucker W, Parsous FM, Maher CF (eds), Martinus. Nijhoff publishers Dortrecht 1990; p 679.
2. Ahmet KY, Varghesse Z, Wills MR. Long-term effect of small doses of 1.25 (OH)2 cholecalciferol in renal os-
teodystrophy. Lancet 1978; i: 629-632.
3. Madsen S, Olgoard K. Long-term trial of 1 alfa hydroxycholecalciferol in adults with chronic renal fai¬lure. Eur J Clin Pharmacol 1970; 13: 401-408.
4. Cherrad DJ, Coburn JW, Brickman AS. Skeletal respon¬se to treatment with 1.25 (OH)2 cholecalciferol in renal failure. Contrib Nephrol 1980; 18: 92-97.
5. Cantley LK, Russel KJ, Lettieri D. 1.25 (OH)2 cholecal-
ciferol supresses parathyroid hormone secretion from parathyroid cells in tissue culture. Endocrinology 1975; 117:2114-2119.
6. Russel J, Lettieri D, Sherwood LH. Suppression by 1.25 (OH)2 cholecalciferol of transcription of the parathyroid hormone gene. Endocrinology 1986; 119: 2864-2866.
7. Silver J, Naveb-Many T, Mayer H. Regulation by vita¬min D metabolites of parathyroid hormone gene trans¬cription in vivo in the rat. J Clin Invest 1986; 78: 1296¬1301.
8. Slatopolsky E, Weerts C, THielan J, et al. Marked supp¬ression of secondary hyperparathyroidism by intraveno¬us administration of 1.25 (OH)2 cholecalferol in uremic
patients. J Clin Invest 1984; 74: 2136-2143.
95
9. Dunlay R, Rodriguez M, Felsenfelt AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989; 36: 1093-1098.
10. Delmez JA, Tindra C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1.25 (OH)2 cholecalci-ferol. A role for increased sensitivity to calcium. J Clin Invest 1989; 83: 1349-1355.
11. Fukagawa M, Okazaki R, Takanu K, et al. Regression of parathyroid hyperplasia by calcitriol pulse therapy in pa¬tients on long term dialysis. N Engl J Med 1990; 323:
421426.
12. Kwan JTC, Almound MK, Beer JC et al. Pulse oral cal-citriol in uremic patients: Rapid modification of parath¬yroid response to calcium. Nephrol Dial Transplant 1992; 7: 829-834.
13. Andress DL, Norris KC, Coburn JW et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl Med 1989; 321: 274-279. '
14. Fischer ER, Harris DCh. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clinical Nephro-logy 1993; 40: 216-220.
15. Tsukamoto Y, Nomura M, Kikawada R, et al. The oral 1.25 (OH)2 cholecalciferol pulse theray in hemodilaysis patients with severe secondary hyperparathyroidism. Nephron 1991; 57: 23-28.
16. Muramoto H, Haruki K, Yoshimura A, et al. Treatment of refractory hyperparathyroidism in patients on hemo-dialysis by intermittent oral administration of 1.25
(OH)2 cholecalciferol. Nephron 1991; 58: 288-294.
17. Malberti F, Sunan M, Cosci P. Improvement of secon-dery hyperparathyroidizm and reduction of the set point of calcium after intravenous calcitriol. Kidney Int 1993;
43 (suppl. 41): 125-130.
18. Aim de Francisko M, Prieto JA, Amado SC, et al. Dialy¬sis membranes and PTH changes during hemodialysis.
Nephrol Dial Transpl (abst.) 1992; 7: 753.
19. Fernandes E, Bertlu Ma, Cao G, et al. Hyperphosphate-mia stimulates PTH secretion by a direct, calcium inde¬pendent mechanism. Nephrol Dial Transpl (abst.) 1993;
7: 767.
20. Moriniere Ph, Esper N El, Viron B, et al. Improvement of severe secondary hyperparathyroidism in dialysis pa¬tients by intravenous 1 a (OH) cholecalciferol oral cal¬cium carbonate and low dialysate calcium. Kidney Int 193; 43 (suppl. 41): 121-124.
21. Klehr HH, Hristea D, Klein B, Paar D. Treatment of se¬vere secondary hyperparathyroidism with oral calcitriol pulse therapy depending on body weight. Nephrol Dial
Transpl 1992; 7: 760 (abstract).
22. Van der Merve WM, Rodger RS C, Grant AC, et al.
Low calcium dialysate and high dose oral calcitriol in the treatment of secondary hyperparathyroidism in he-modialysis patients. Nephrol Dial Transpl 1990; 5: 874¬877.
23. Massry SG, Golstein DA, Malluche HH. Current status of the use of 1.25 (OH)2 cholecalciferol in the manage¬ment of renal osteodystrophy. Kidney Int 1980; 18: 409¬419.
24. Pierides AM, Ellis HA, Dellagrammatikas H, et al. 1.25
(OH)2 cholecalciferol in renal osteodystrophy. Arch Dis
Child 1972; 52: 464472.
25. Klaus G, Mebls O, Flinderer J, Ritz E. Is Intermittent oral calcitriol safe and effective in renal secondary
hyperparathyroidism ? Lancet 1991; 337: 800-801.
96
Thank you for copying data from http://www.arastirmax.com